The Insomnia Market Size was valued at USD 4.85 Billion in 2023. The Global Insomnia industry is projected to grow from USD 5.22 Billion in 2024 to USD 8.64 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.8% during the forecast period (2024 - 2032). The increasing number of people with insomnia, the rise in psychological disorders, and the ever-increasing noise levels in cities are the key market drivers enhancing market growth.
Key market drivers supporting market growth include the rising prevalence of sleep problems, the prevalence of mental health issues, and the relentless increase in urban noise. Insomnia and parasomnias are two of the most common sleep disorders, and they are contributing factors to the expansion of the insomnia market. Insomnia is a common symptom of mental depression. As a result, the rising prevalence of depression has contributed to the CAGR of the global market in recent years.
In addition, there are rumored negative consequences on sleep quality from the long-term use of medications for chronic disease therapy. As a result, rising rates of chronic diseases like cancer are fueling the market's expansion. Revenue increase in the insomnia industry can be directly attributed to the negative effects of cancer treatment on patients' ability to get a good night's rest. The market expansion of insomnia can also be attributed to the increase in work-related stress. Poor sleep quality is a direct result of the increase in work and the busy pace of modern life.
The proliferation of sleep disorder treatment and diagnosis facilities further boosts the industry. Sleep diagnostic centers serve as diagnostic laboratories for identifying sleep disorders, while insomnia treatment facilities help people improve the quality of their sleep.
In addition, the rising popularity of alternatives to pharmaceutical sleep aids is fueling the industry. People's mental health is often thought to play a role in their inability to sleep. As a result, the insomnia market is fueled by non-pharmacological therapies like hypnosis, yoga, and cognitive behavioral therapy, which aim to improve a person's mental state.
In August 2023, SUSMED, Inc. (TOKYO:4263) announced that it has achieved regulatory consent by SUSMED Med CBT-i® App for Insomnia from the Ministry of Health, Labour and Welfare (“MHLW”) (the “product”). Currently, the company is in the process of applying for coverage and launching its market. Insomnia is a sleep disorder, which also shows itself through difficulty sleeping, staying asleep or early wakefulness among many other signs. Moreover, to be one of the most common conditions seen by primary care physicians. According to a national survey in Japan, 8.3% of respondents complained of difficulty falling asleep, while 21.4% suffered from insomnia1. Insomnia is recognized as an important social problem that affects the quality of life for patients because long-lasting cases increase the risk of psychiatric disorders, including depression and anxiety disorders. At present, sleeping pills are widely used for treating insomnia in Japan2.
The Jinglebread collection has finally arrived on store shelves this August through Insomnia Cookies, a limited-edition holiday treats lineup inspired by gingerbread that pushes all things festive flavor-wise. From classic jinglebread cookies & mini versions to dunkable big & lil’ dippers ready to mingle with cream cheese frosting, the limited-edition lineup will be available until December 31st for local delivery. While supplies last, the selection will be sold exclusively in-store. In October, Insomnia Cookies celebrated 20 years of delivering cookies. The bakery chain was founded in 2003 at the University of Pennsylvania by Seth Berkowitz, who was then a student. Now, it has more than 250 firm-owned positions in the United States and other new ones in Canada and Great Britain.
Pear Therapeutics launched a smartphone app for chronic insomnia which is a prescription product available with a doctor’s recommendation back in November 2020. The Somryst app was approved in March of this year by the FDA. It is one of the earliest products to come through the agency's pilot program for software and developers while they are being developed. Patients who are aged 22 and older may access this application, which applies cognitive behavioral therapy to insomnia just like what many expert clinics would offer at first contact. Its algorithm provides customized lessons and challenges running within six to nine weeks period, thereby restricting sleep time to a particular schedule, resulting in better quality sleep over time.
April 2023:Bukwang Pharmaceutical announced the release of Zaledeep Cap. (containing zaleplon), a medication for the treatment of insomnia. Bukwang hopes that the introduction of Zaledeep Cap., the first medication in Korea to use zaleplon as its principal ingredient, would give those seeking help for insomnia a new option. Studies have shown that Zaleplon has a rapid beginning of action, quickly induces sleep in individuals with insomnia, a short half-life, minimally disrupts daily life, and produces minimal rebound insomnia. The FDA has already given marketing approval to the non-benzodiazepine class medication zaleplon for the treatment of insomnia.
The prevalence of different types of sleep disorders, such as insomnia and parasomnias, an increase in mental depression, and other painful conditions drives the growth of the insomnia market size. Mental depression results in difficulty in sleep. For instance, the World Health Organization (WHO) reported that around 280 million population ly suffers from depression. Thus, the increase in mental depression across the population enhanced the market CAGR across the globe in recent years.
Furthermore, long-term medication consumption for chronic disease treatment has some side effects, which are believed to affect the patient's quality of sleep. Thus, an increase in the prevalence of chronic diseases, such as cancer, drives the growth of the market. For instance, according to the National Institute of Cancer (NIC), an estimated 1,806,590 new cancer cases were diagnosed in the US in 2020. Cancer chemotherapy results in various side effects on the patient's body and affects the quality of sleep in patientsdriving the growth of the insomnia market revenue.
In addition, the surge in work-related stress contributes to the maket growth of the insomnia. The rise in workload and hectic work schedules lead to poor quality of sleep. Many people work odd shifts, such as security officers, and the manufacturing industries operate for 24 hours. These odd-time work shifts affect the quality and cycle of sleep. An increase in the number of insomnia centers and sleep diagnostic centers contributes to the growth of the market. Insomnia centers assist people in improving their sleep quality, and sleep diagnostic centers are used as a diagnostic labs for detecting sleep disorders.
Furthermore, increasing the adoption of non-pharmacological sleep therapy drives the market's growth. Insomnia is commonly associated with the mental condition of the person. Hence, non-pharmacological therapy, such as hypnotherapy, yoga, and cognitive behavioral therapy, focuses on improving a person's mental state and driving the insomnia industry.
The market segments of insomnia, based ontherapy types, includes pharmacological and non-pharmacological therapy. The non-pharmacological therapysegment held the majority share 2022 of the insomnia market revenue due to the advancements in non-pharmacological therapy for sleep, and new product launches drive the market growth. However, pharmacological therapyis the fastest-growing category over the forecast perioddue to advancements in pharmacological therapy for sleep.
The insomnia market data has been bifurcated into the drug formulation, including capsules, tablets and others. The tablet segment dominated the market in 2022 and is projected to be the faster-growing category during the forecast period 2022-2030. The tablets help the natural transition from sleeplessness to sleep by interfering with the arousal system's wakefulness-promoting orexin neurons. Suvorexant advancements sleep onset, as well as sleep maintenance. However, capsules are the fastest-growing category over the forecast period due to the increasing product approvals and product development activities.
Figure 1 Insomnia Market, by Drug Formulation, 2022 & 2030 (USD Billion)
Source Secondary Research, MRFR Database, Primary Research and Analyst Review
The market data of insomnia has been bifurcated into the type of disease condition, including poor quality of sleep, sleep maintenance and others.The sleep maintenance segment dominated the market in 2022 and is projected to be the faster-growing category during the forecast period, 2022-2030. Medical devices have benefits like the rapid onset of sleep and longer sleep maintenance among patients. However, poor sleep quality is the fastest-growing category over the forecast period due to the increase in workload and hectic work schedules.
January 2023:The FDA has given Zydus Lifesciences Ltd final approval to sell its generic version of Triazolam pills, which are indicated for the short-term treatment of insomnia. US regulators have given the business the go light to sell Triazolam pills in 0.125 mg and 0.25 mg doses, the manufacturer said in a regulatory filing. The medication is prescribed for short-term use by those who suffer from insomnia. It accomplishes its sleep-inducing effects by decreasing brain activity.
By Region, the study deliversmarket insights into North America, Asia-Pacific, Europe and the Rest of the World. The North America insomnia market accounted for USD 0.68billion in 2022 and is anticipated to exhibit a significant CAGR growth during the study period. Growing demand for sleep disorder treatment in the US and Canada and an increasing prevalence of sleep disorders increased awareness and high healthcare spending in the region. Further, the US market of insomnia held the largest market share, and the Canada market of insomnia was the fastest-growing market in the North Americaregion.
Further, the prominent countries studied in the market report are The U.S, Canada, France, the UK, Italy, Germany, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 INSOMNIA MARKET SHARE BY REGION 2022 (%)
Source Primary Research, Secondary Research, MRFR Database and Analyst Review
Europe insomnia market accounts for the second-largest market share over the forecast period. This is attributed to the increasing prevalence of sleep disorders, the existence of major market players, and frequent product introduction coupled with increasing government funding for insomnia treatments. Further, the Germany market of insomnia held the largest market share, and the UK market of insomnia was the fastest-growing market in the Europe region.
The Asia-Pacific Insomnia market is expected to grow at the fastest CAGR from 2024 to 2032. This is owing to the high prevalence of the target disease, and it is estimated that one out of five people in Japan suffer from it. Emerging economies such as India, China, and Indonesia have been using generics and branded generics due to the economic pricing of generic alternatives. Moreover, the China market of insomnia held the largest market share, and the India market of insomnia was the fastest-growing market in the Asia-Pacific region.
Insomnia Key Market Players & Competitive Insights
Major market players are expending a lot of money on R&D to enhance their product lines, which will allow the market of insomnia to grow even more. Major market participants are also taking various strategic initiatives to expand their worldwide footprint, with key market developments such as new contractual agreements, product launches, mergers and acquisitions, improved investments, and collaboration with other organizations. Competitors in the insomnia industry must offer cost-effective items to enhance and survive in an increasingly competitive and growing market environment.
Manufacturing locally to reduce operating costs is one of the primary enterprise strategies manufacturers adopt in the insomnia industry to benefit clients and expand the market sector. The insomnia market major player such as Pfizer Inc. (UK), Sanofi (France), GlaxoSmithKline Plc. (UK), and others are working on enhancing the market demand by investing in R&D activities.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical firm. It primarily focuses on developing and commercializing a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. In January 2021, Royalty Pharma PLC and Minerva Neurosciences Inc. entered an agreement via which Royalty Pharma will receive Minerva's royalty interest in seltorexant. It is a selective orexin two receptor antagonist and is presently in Phase 3 development for treating primary depressive disorder (MDD) with insomnia symptoms.
Also, Eisai Co., Ltd. produces prescription drugs and medical equipment and sells mainly to sales agents and subsidiaries. Through its subsidiary, the Company produces and sells diagnostic drugs. Eisai also markets its products through related companies in the US, Europe, and Asia. The Company also manufactures and sells foods, livestock feeds, chemicals, and agrochemicals. In February 2021, Eisai Limited is, the Canadian subsidiary of Eisai Inc. approved Canadian authorization for its new non-sedative prescription medication, DAYVIGO (lemborexant). In both 10 mg and 5 mg dosages, DAYVIGO is taken for the therapy of insomnia, characterized by problems with sleep onset and/or sleep maintenance.
October 2022:Idorsia Pharmaceuticals Japan declared positive top-line developments of the Japanese Phase 3 study investigating 50 and 25 mg doses of Idorsia's dual orexin receptor adversary, daridorexant, in 490 randomized adult and elderly patients (30.1% ≥ 65 years) with insomnia disorder.
June 2022:Pear Therapeutics reported interim follow-up real-world data from a decentralized trail that showed treatment with Somryst, one of the FDA-authorised digital therapeutics for treating chronic insomnia. This device significantly decreased symptoms of insomnia, anxiety, and depression severity.
May 2022:Idorsia Ltd received marketing authorization from the European Commission for QUVIVIQ, which is suggested for treating adult patients with insomnia indicated by symptoms present for approx three months and considerable impact on daytime functioning.
January 2022:Idorsia obtained permission from the US FDA for QUVIVIQ 50 and 25 mg for treating adults with insomnia, characterized by sleep onset and sleep maintenance difficulties.
| Report Attribute/Metric | Details |
| Market Size2023 | USD 4.85 billion |
| Market Size 2024 | USD 5.22 billion |
| Market Size 2032 | USD 8.64 billion |
| Compound Annual Growth Rate (CAGR) | 5.8% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019- 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Growth Factors, Market Competitive Landscape, and Trends |
| Segments Covered | Types Of Therapy, Drug Formulation, Type Of Diseases Condition and Region |
| Geographies Covered | North America, Asia-Pacific, Europe, and the Rest of the World |
| Countries Covered | The U.S, Canada, France, the U.K., Germany, Italy, Spain, China, Japan, India, South Korea, Australia, and Brazil |
| Key Companies Profiled | Eisai, Co. (Japan), Pfizer, Inc. (US), Merck & Co Inc (US), Sanofi (France), Takeda Pharmaceutical Company (Japan), Meda Consumer Healthcare Inc (US), Pernix Therapeutics (US), Purdue Pharma LP (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), and Flynn Pharma (UK.) |
| Key Market Opportunities | ·      Increasing stressful work conditions ·      Growing demand for OTC drugs |
| Key Market Dynamics | ·      Rising incidence of insomnia |
Frequently Asked Questions (FAQ) :
The global insomnia market size was valued at USD 4.85 Billion in 2023.
The global market is projected to grow at a CAGR of 5.8% during the forecast period, 2024-2032.
North America had the largest share of the global market
The key players in the market are Eisai, Co. (Japan), Pfizer, Inc. (US), Merck & Co Inc (US), Sanofi (France), Takeda Pharmaceutical Company (Japan), Meda Consumer Healthcare Inc (US), Pernix Therapeutics (US), and Purdue Pharma LP (US).
The non-pharmacological therapy category dominated the market in 2023.
Tablets had the largest share of the global market.
Sleep maintenance had the largest share of the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
